Clinical Trial Update: Study to Evaluate Adverse Events and Change in Disease Activity in Participants Between 6 and 17 Years With Moderate to Severe Plaque Psoriasis Treated With Subcutaneous (SC) Injection of Risankizumab Who Have Completed Participation in Study M19-977 [Phase 3]

View source ↗

Summary

This update reports on adverse events and changes in disease activity in pediatric participants aged 6 to 17 with moderate-to-severe plaque psoriasis who comple…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Plaque Psoriasis

Drugs mentioned

• SKYRIZI (risankizumab-rzaa)

Snippet

Sponsor: AbbVie | Conditions: Psoriasis | Phase 3 | Status: ACTIVE_NOT_RECRUITING